2023年6月最新SCI影响因子数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | JOURNAL OF CLINICAL ONCOLOGY J CLIN ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.9
50人评分
我要评分
声誉 10.0 影响力 9.9 速度 9.4 | |||||||||||||||||||||
| 期刊ISSN | 0732-183X | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1527-7755 | |||||||||||||||||||||
| 2022-2023最新影响因子 （数据来源于搜索引擎） | 45.3 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2023年9月27日：15.57 | |||||||||||||||||||||
| 2022-2023自引率 | 2.20%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 37.6 | |||||||||||||||||||||
| h-index | 494 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 | The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer. Print ISSN: 0732-183X | |||||||||||||||||||||
| 期刊官方网站 | http://jco.ascopubs.org/ | |||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/JCO-ASCOPUBS | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足JOURNAL OF CLINICAL ONCOLOGY的语言要求，还能让JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, USA, VA, 22314 | |||||||||||||||||||||
| 出版商 | American Society of Clinical Oncology | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Biweekly | |||||||||||||||||||||
| 出版年份 | 1983 | |||||||||||||||||||||
| 年文章数 | 340点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 25.40% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 87.35% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2022-2023年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0732-183X%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均2月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约20% | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在JOURNAL OF CLINICAL ONCOLOGY顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH) Author: Peng, Zhenwei; Fan, Wenzhe; Zhu, Bowen; Wang, Guoying; Sun, Junhui; Xiao, Chengjiang; Huang, Fuxi; Tang, Rong; Cheng, Yu; Huang, Zhen; Liang, Yuchuang; Fan, Huishuang; Qiao, Liangliang; Li, Fuliang; Zhuang, Wenquan; Peng, Baogang; Wang, Jiping; Li, Jiaping; Kuang, Ming Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 1, pp. 117-+. DOI: 10.1200/JCO.22.00392 PubMed DOI |
| 2. | Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial Author: Zhang, Haiyan; Fan, Zhiping; Huang, Fen; Han, Lijie; Xu, Yajing; Xu, Na; Deng, Lan; Wang, Shunqing; Lin, Dongjun; Luo, Xiaodan; Zhang, Qing; Liu, Xiaodan; Li, Xudong; Liang, Xinquan; Xie, Shuangfeng; Qu, Hong; Yu, Sijian; Zhou, Hongsheng; Shi, Pengcheng; Xuan, Li; Lin, Ren; Liu, Hui; Jin, Hua; Sun, Jing; Liu, Qifa Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 343-+. DOI: 10.1200/JCO.22.00767 PubMed DOI |
| 3. | Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial Author: Drilon, Alexander; Subbiah, Vivek; Gautschi, Oliver; Tomasini, Pascale; de Braud, Filippo; Solomon, Benjamin J.; Tan, Daniel Shao-Weng; Alonso, Guzman; Wolf, Juergen; Park, Keunchil; Goto, Koichi; Soldatenkova, Victoria; Szymczak, Sylwia; Barker, Scott S.; Puri, Tarun; Bence Lin, Aimee; Loong, Herbert; Besse, Benjamin Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 385-+. DOI: 10.1200/JCO.22.00393 PubMed DOI |
| 4. | Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01) Author: Wang, Zhijie; Wu, Lin; Li, Baolan; Cheng, Ying; Li, Xiaoling; Wang, Xicheng; Han, Liang; Wu, Xiaohong; Fan, Yun; Yu, Yan; Lv, Dongqing; Shi, Jianhua; Huang, Jianjin; Zhou, Shaozhang; Han, Baohui; Sun, Guogui; Guo, Qisen; Ji, Youxin; Zhu, Xiaoli; Hu, Sheng; Zhang, Wei; Wang, Qiming; Jia, Yuming; Wang, Ziping; Song, Yong; Wu, Jingxun; Shi, Meiqi; Li, Xingya; Han, Zhigang; Liu, Yunpeng; Yu, Zhuang; Liu, An-Wen; Wang, Xiuwen; Zhou, Caicun; Zhong, Diansheng; Miao, Liyun; Zhang, Zhihong; Zhao, Hui; Yang, Jun; Wang, Dong; Wang, Yingyi; Li, Qiang; Zhang, Xiaodong; Ji, Mei; Yang, Zhenzhou; Cui, Jiuwei; Gao, Beili; Wang, Buhai; Liu, Hu; Nie, Lei; He, Mei; Jin, Shi; Gu, Wei; Shu, Yongqian; Zhou, Tong; Feng, Jian; Yang, Xinmei; Huang, Cheng; Zhu, Bo; Yao, Yu; Tang, Xiongwen; Yu, Jianjun; Maher, Ellen; Feng, Hui; Yao, Sheng; Keegan, Patricia; Wang, Jie Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 3, pp. 651-+. DOI: 10.1200/JCO.22.00727 PubMed DOI |
| 5. | BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers Author: Sun, Jie; Chu, Futao; Pan, Jiani; Zhang, Yaxin; Yao, Lu; Chen, Jiuan; Hu, Li; Zhang, Juan; Xu, Ye; Wang, Xiaojia; Cao, Wenming; Xie, Yuntao Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 5, pp. 991-+. DOI: 10.1200/JCO.22.00833 PubMed DOI |
| 6. | Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial Author: Hillmen, Peter; Eichhorst, Barbara; Brown, Jennifer R.; Lamanna, Nicole; O'Brien, Susan M.; Tam, Constantine S.; Qiu, Lugui; Kazmierczak, Maciej; Zhou, Keshu; Simkovic, Martin; Mayer, Jiri; Gillespie-Twardy, Amanda; Shadman, Mazyar; Ferrajoli, Alessandra; Ganly, Peter S.; Weinkove, Robert; Grosicki, Sebastian; Mital, Andrzej; Robak, Tadeusz; Osterborg, Anders; Yimer, Habte A.; Salmi, Tommi; Ji, Meng; Yecies, Jessica; Idoine, Adam; Wu, Kenneth; Huang, Jane; Jurczak, Wojciech Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 5, pp. 1035-+. DOI: 10.1200/JCO.22.00510 PubMed DOI |
| 7. | Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial Author: Qin, Shukui; Chen, Zhendong; Fang, Weijia; Ren, Zhenggang; Xu, Ruocai; Ryoo, Baek-Yeol; Meng, Zhiqiang; Bai, Yuxian; Chen, Xiaoming; Liu, Xiufeng; Xiao, Juxiang; Ho, Gwo Fuang; Mao, Yimin; Wang, Xin; Ying, Jieer; Li, Jianfeng; Zhong, Wenyan; Zhou, Yu; Siegel, Abby B.; Hao, Chunyi Journal: JOURNAL OF CLINICAL ONCOLOGY. 2023; Vol. 41, Issue 7, pp. 1434-+. DOI: 10.1200/JCO.22.00620 PubMed DOI |
| 8. | Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial. Author: Jiang J1, Li Y1, Shen Q1,2, Rong X1, Huang X1, Li H1, Zhou L3, Mai HQ4, Zheng D5, Chen MY4, Xu Y1, Li J4, Hui X6, Simone CB 2nd7, Gaertner J8, Argyriou AA9, Chow E10, Chen P3, Tang Y1. Journal: J Clin Oncol. 2019 Jan 10;37(2):135-143. doi: 10.1200/JCO.18.00896. Epub 2018 Nov 20. PubMed DOI |
| 9. | PHOENIX-GC Trial: Underpowered for Significant Results? Author: Li Z1, Xue K1, Ying X1, Ji J1. Journal: J Clin Oncol. 2019 Jan 10;37(2):167. doi: 10.1200/JCO.18.00364. Epub 2018 Nov 26. PubMed DOI |
| 10. | Is SLFN11 a Promising Predictive Biomarker of Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Small-Cell Lung Cancer? Not Yet! Author: Liang F1. Journal: J Clin Oncol. 2019 Jan 20;37(3):259. doi: 10.1200/JCO.18.00993. Epub 2018 Nov 29. PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共2条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
